Abstract 1364P
Background
SAF-189s is a next-generation inhibitor of ALK/ROS1 tyrosine kinase, which has been shown to have anti-tumor activity against ALK/ROS1 fusion-positive non-small-cell lung cancer (NSCLC), including CNS activity due to its ability to penetrate the blood-brain barrier. Here we present a circulating tumor DNA (ctDNA) biomarker analysis of patients (pts) with advanced, ALK-rearranged NSCLC treated in phase 2a study.
Methods
Tumor tissue samples were collected from all enrolled pts for ALK-fusion detection by VENTANA ALK (D5F3) IHC assay. Plasma samples were collected at baseline and disease progression. Next-generation sequencing for ctDNA was done using Lung cancer 180-gene panel (Genetron). PFS was evaluated according to ALK alteration status.
Results
By the cut-off date of Dec 13th, 2021 (median PFS follow-up 11 mo), a total of 143 NSCLC ALK-fusion positive pts had been enrolled and treated with SAF-189s (80 mg, n=19; 120 mg, n=47, 160 mg, n=64; 210 mg, n=13), including 100 ALKi-naïve pts and 43 ALKi-refractory pts (received crizonitib and/or next-generation ALKi). ctDNA at baseline was tested in 143 pts with a ALK-fusion positivity rate of 53.8% (77/143). The main fusion partner of ALK was EML4, accounting for 93.6% (73/78). The most common fusion variants were v3 (34.5%, 27/78), v1 (28.2%, 22/78), and v2 (10.3%, 8/78). Pts with v1 variants showed a longer mPFS than v3 variants (16.5 mo vs. 13.8 mo, p=0.188). There was no significant difference in the distribution of ALK fusion variants between ALKi-naïve and ALKi-refractory groups. Of 25 pts who progressed with SAF-189s, two ALK mutations, G1202R and I1179T, were newly identified in 3 pts. I1179T has not been previously reported and is speculated to be a novel ALK-resistant mutation. TP53 co-mutations were detected in 47% pts, but it was not shown to have a significant effect on outcomes. Gene co-occurrence survival analysis showed that mPFS of pts harboring FAT3/FAT4 mutations were significantly shorter than those without FAT3/FAT4 mutations (8.9 mo vs 16.5 mo, p=0.012).
Conclusions
Clinical utility of ctDNA was demonstrated, not only at baseline by identifying fusion types and subgroups of ALK+ NSCLC pts that may benefit more from SAF-189s, but also at progression by tracking ALK-resistant mutations.
Clinical trial identification
NCT04237805.
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
Funding
Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1068P - Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in melanoma and lung cancer models
Presenter: Salvatore Cortellino
Session: Poster session 19
1070P - Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastases
Presenter: Tianqi Gu
Session: Poster session 19
1071P - Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database
Presenter: Zimu Li
Session: Poster session 19
1072P - DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
Presenter: Sina Fellermeier-Kopf
Session: Poster session 19
1073P - Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models
Presenter: Ilya Tsimafeyeu
Session: Poster session 19
1074TiP - A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Presenter: Martin Gutierrez
Session: Poster session 19
1075TiP - A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
Presenter: Ecaterina Dumbrava
Session: Poster session 19
1076TiP - First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
Presenter: Sunil Babu
Session: Poster session 19
1077TiP - TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Presenter: Harshabad Singh
Session: Poster session 19